SG10201407538WA - Intravenous formulations of neurokinin-1 antagonists - Google Patents

Intravenous formulations of neurokinin-1 antagonists

Info

Publication number
SG10201407538WA
SG10201407538WA SG10201407538WA SG10201407538WA SG10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA SG 10201407538W A SG10201407538W A SG 10201407538WA
Authority
SG
Singapore
Prior art keywords
neurokinin
antagonists
intravenous formulations
pharmaceutical compositions
methods
Prior art date
Application number
SG10201407538WA
Inventor
Jiansheng Wan
Pranav Gupta
David Monteith
Soumendu Bhattacharya
Original Assignee
Opko Health Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Opko Health Inc filed Critical Opko Health Inc
Publication of SG10201407538WA publication Critical patent/SG10201407538WA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A01N43/42—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof

Abstract

Pharmaceutical compositions for intravenous administration comprising the compound of Formula I, or pharmaceutically acceptable salts, hydrates or prodrugs thereof are described herein. Methods of preparing the pharmaceutical compositions and methods for treating nausea and/or emesis with the pharmaceutical compositions are also described herein. FIGURE 4. 72
SG10201407538WA 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists SG10201407538WA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US23412909P 2009-08-14 2009-08-14

Publications (1)

Publication Number Publication Date
SG10201407538WA true SG10201407538WA (en) 2015-01-29

Family

ID=43586486

Family Applications (2)

Application Number Title Priority Date Filing Date
SG10201407538WA SG10201407538WA (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists
SG2012010146A SG178403A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG2012010146A SG178403A1 (en) 2009-08-14 2010-08-12 Intravenous formulations of neurokinin-1 antagonists

Country Status (15)

Country Link
US (2) US9101615B2 (en)
EP (2) EP3143996A1 (en)
JP (2) JP5860399B2 (en)
KR (1) KR101834577B1 (en)
CN (2) CN105503870A (en)
AU (1) AU2010282483B2 (en)
BR (1) BR112012003263A2 (en)
CA (1) CA2770403C (en)
ES (1) ES2609640T3 (en)
IL (1) IL217942A0 (en)
MX (1) MX336071B (en)
RU (2) RU2017145628A (en)
SG (2) SG10201407538WA (en)
TW (2) TW201604195A (en)
WO (1) WO2011019911A1 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102276606B (en) 2006-04-05 2013-06-12 欧科生医股份有限公司 Tosylate crystalline salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
AR060303A1 (en) 2006-04-05 2008-06-04 Schering Corp SALM PHARMACEUTICAL FORMULATIONS OF 8- [1- (3,5 -BIS- (TRIFLUOROMETIL) PHENYL) -ETOXIMETILE] -8-PHENYL-1,7 -DIAZA-ESPIRO [4.5] DECAN -2- ONA AND TREATMENT METHODS USING SAME
AR066191A1 (en) 2007-03-22 2009-08-05 Schering Corp PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
CN102203062B (en) 2008-09-05 2014-12-17 欧科生医股份有限公司 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2017145628A (en) 2009-08-14 2019-02-19 ОПКО Хельс, Инк. COMPOSITIONS OF NEUROKININ-1 ANTAGONISTS FOR INTRAVENOUS INTRODUCTION
TW201605852A (en) * 2013-09-26 2016-02-16 美國禮來大藥廠 Novel compounds and use for preparation of tau imaging agents and tau imaging formulations
KR102424837B1 (en) 2014-09-19 2022-07-25 헤론 테라퓨틱스 인코포레이티드 Emulsion formulations of aprepitant
WO2017044693A1 (en) 2015-09-11 2017-03-16 Chase Pharmaceuticals Corporation Muscarinic combination and its use for combating hypocholinergic disorders of the central nervous system
US9974742B2 (en) 2016-02-01 2018-05-22 Heron Therapeutics, Inc. Emulsion formulations of an NK-1 receptor antagonist and uses thereof
CA3013288A1 (en) * 2016-02-01 2017-08-10 Heron Therapeutics, Inc. Emulsion comprising an nk-1 receptor antagonist
US20190175702A1 (en) * 2016-08-03 2019-06-13 Zhuhai Beihai Biotech Co., Ltd. Formulations of fosaprepitant and aprepitant
WO2018094394A1 (en) * 2016-11-21 2018-05-24 Zhuhai Beihai Biotech Co., Ltd. Formulations of rolapitant
IL269875B1 (en) 2017-04-10 2024-02-01 Chase Therapeutics Corp Nk1-antagonist combination and method for treating synucleinopathies
CN110996911B (en) * 2017-06-26 2023-01-17 福多兹制药公司 Aprepitant nano-microcapsule preparation as well as method and application thereof
WO2019006050A1 (en) 2017-06-30 2019-01-03 Chase Therapeutics Corporation Nk-1 antagonist compositions and methods for use in treating depression
CN109200018A (en) * 2017-07-04 2019-01-15 南京诺瑞特医药科技有限公司 Containing how the smooth microemulsion formulation of appropriate pyrrole
CN108703950B (en) * 2018-08-27 2021-04-20 辅必成（上海）医药科技有限公司 Emulsion injection of Lapiaptan
CN109453115A (en) * 2018-12-25 2019-03-12 广州白云山汉方现代药业有限公司 A kind of smooth intravenous injection emulsion of roller and its preparation method and application
CN109394693A (en) * 2018-12-25 2019-03-01 广州白云山汉方现代药业有限公司 A kind of smooth emulsion of roller and its preparation method and application
US20220380393A1 (en) 2019-06-28 2022-12-01 Shanghai Shengdi Pharmaceutical Co., Ltd Neurokinin-1 antagonist
WO2021198255A1 (en) 2020-04-03 2021-10-07 Nerre Therapeutics Limited An nk-1 receptor antagonist for treating a disease selecting from sepsis, septic shock,, acute respiratory distress syndrome (ards) or multiple organ dysfunction syndrome (mods)
CA3177477A1 (en) 2020-06-02 2021-12-09 Nerre Therapeutics Limited Neurokinin (nk)-1 receptor antagonists for use in the treatment of pulmonary fibrosis conditions promoted by mechanical injury to the lungs
JP2024501994A (en) 2020-12-25 2024-01-17 上海盛迪医▲葯▼有限公司 Combination use of NK1 antagonist prodrug compound and 5-HT3 receptor antagonist
WO2023134725A1 (en) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 Pharmaceutical composition comprising neurokinin-1 antagonist prodrug compound
WO2023134723A1 (en) * 2022-01-12 2023-07-20 江苏恒瑞医药股份有限公司 Crystal form of neurokinin-1 antagonist prodrug compound

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0338372A3 (en) * 1988-04-22 1991-10-09 American Cyanamid Company Solubilized pro-drugs
DE69034035T2 (en) * 1989-07-07 2004-01-22 Endorecherche Inc., Ste-Foy METHOD FOR TREATING ANDROGEN DISEASES
US5610140A (en) * 1991-04-01 1997-03-11 Cortech, Inc. Bradykinin receptor antagonists with neurokinin receptor blocking activity
AU678409B2 (en) 1992-10-28 1997-05-29 Merck Sharp & Dohme Limited 4-arylmethyloxymethyl piperidines as tachykinin antagonists
AU682838B2 (en) 1992-12-14 1997-10-23 Merck Sharp & Dohme Limited 4-aminomethyl/thiomethyl/sulfonylmethyl-4-phenylpiperidines as tachykinin receptor antagonists
GB9305718D0 (en) * 1993-03-19 1993-05-05 Glaxo Group Ltd Medicaments
ATE170174T1 (en) 1994-01-13 1998-09-15 Merck Sharp & Dohme GEM-BIS-SUBSTITUTED AZAZYCLIC TACHYKININ ANTAGONISTS
KR100405116B1 (en) 1995-02-28 2004-02-05 아벤티스 파마슈티칼스 인크. Pharmaceutical compositions for piperidino alkanol compounds
SE9503143D0 (en) * 1995-09-12 1995-09-12 Astra Ab New preparation
GB9601680D0 (en) 1996-01-27 1996-03-27 Pfizer Ltd Therapeutic agents
ATE265209T1 (en) 1996-07-17 2004-05-15 Merck & Co Inc ALTERING THE CIRCADIC RHYTHM WITH NON-PEPTID NEUROKININ-1 RECEPTOR ANTAGONISTS
WO1998047514A1 (en) 1997-04-24 1998-10-29 Merck Sharp & Dohme Limited Use of an nk-1 receptor antagonist and an ssri for treating obesity
JP3571511B2 (en) * 1997-11-11 2004-09-29 トーアエイヨー株式会社 Transdermal formulation
EP1140074A1 (en) * 1998-12-23 2001-10-10 NPS Allelix Corp. Indole and indolizidine derivatives for the treatment of migraine
EP1185301A1 (en) 1999-05-24 2002-03-13 Sonus Pharmaceuticals, Inc. Emulsion vehicle for poorly soluble drugs
CA2393672A1 (en) 1999-12-17 2001-06-21 Schering Corporation Selective neurokinin antagonists
US6436928B1 (en) 1999-12-17 2002-08-20 Schering Corporation Selective neurokinin antagonists
US6499984B1 (en) 2000-05-22 2002-12-31 Warner-Lambert Company Continuous production of pharmaceutical granulation
MY128450A (en) * 2000-05-24 2007-02-28 Upjohn Co 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
EP1368322A4 (en) * 2001-02-12 2004-03-17 Teva Pharma New crystal forms of oxcarbazepine and processes for their preparation
AR038002A1 (en) 2001-11-13 2004-12-22 Schering Corp ANTAGONISTS OF THE RECEIVER OF NEUROQUININA-1, PHARMACEUTICAL COMPOSITIONS AND THE USE OF SUCH ANTAGONISTS FOR THE PREPARATION OF A MEDICINAL PRODUCT
PE20030762A1 (en) * 2001-12-18 2003-09-05 Schering Corp HETEROCYCLIC COMPOUNDS AS NK1 ANTAGONISTS
AU2003277299B2 (en) 2002-04-10 2009-12-10 Conforma Therapeutics Corporation Drug formulations having long and medium chain triglycerides
ATE358482T1 (en) * 2002-07-03 2007-04-15 Schering Corp 1-AMIDO-4-PHENYL-4-BENZYLOXYMETHYL-PIPERIDINE DERIVATIVES AND RELATED COMPOUNDS AS NEUROKININ-1 (NK-1) ANTAGONISTS FOR THE TREATMENT OF VOMITING, DEPRESSION, ANXIETY AND COUGH
US7534913B2 (en) * 2002-07-18 2009-05-19 Teva Pharmaceutica Industries Ltd. Crystalline form of nateglinide
EP1575962A1 (en) * 2002-12-24 2005-09-21 Teva Pharmaceutical Industries Limited Novel crystal forms of olanzapine, methods for their preparation and method for the preparation of known olanzapine crystal forms
GB0321256D0 (en) * 2003-09-11 2003-10-08 Generics Uk Ltd Novel crystalline compounds
EA009941B1 (en) 2003-10-03 2008-04-28 Пфайзер Инк. Imidazopyridine substituted tropane derivatives with ccr5 receptor antagonist activity for the treatment of hiv and inflammation
US20050153999A1 (en) * 2003-12-22 2005-07-14 Schering Corporation Pharmaceutical compositions
CN101006074B (en) * 2004-07-01 2012-02-15 欧科生医股份有限公司 Piperidine derivatives as NK1 antagonists
US7871632B2 (en) 2004-07-12 2011-01-18 Adventrx Pharmaceuticals, Inc. Compositions for delivering highly water soluble drugs
CA2588052A1 (en) * 2004-11-30 2006-06-08 Myriad Genetics, Inc. Therapeutic formulations
CN100367951C (en) 2005-12-16 2008-02-13 石药集团恩必普药业有限公司 Butyl benzene phthalein vein emulsion and its application
TW200800180A (en) * 2006-03-06 2008-01-01 Wyeth Corp Liquid and semi-solid pharmaceutical formulations and processes
AR060303A1 (en) * 2006-04-05 2008-06-04 Schering Corp SALM PHARMACEUTICAL FORMULATIONS OF 8- [1- (3,5 -BIS- (TRIFLUOROMETIL) PHENYL) -ETOXIMETILE] -8-PHENYL-1,7 -DIAZA-ESPIRO [4.5] DECAN -2- ONA AND TREATMENT METHODS USING SAME
CN102276606B (en) 2006-04-05 2013-06-12 欧科生医股份有限公司 Tosylate crystalline salts of 8-[{1-(3,5-bis-(trifluoromethyl) phenyl) -ethoxy}-methyl] -8-phenyl-1,7-diaza-spiro[4.5] decan-2-one and preparation process therefor
CN101110758A (en) 2006-07-21 2008-01-23 华为技术有限公司 Method and system for establishing emergency conversation and proxy function of controlling call conversation
EP2650291B1 (en) * 2006-08-07 2017-10-04 Palau Pharma, S.A. Crystalline Antifungal Compounds
US8263613B2 (en) * 2007-02-16 2012-09-11 Affinium Pharmaceuticals, Inc. Salts, prodrugs and polymorphs of fab I inhibitors
AR066191A1 (en) * 2007-03-22 2009-08-05 Schering Corp PROCESS AND INTERMEDIARIES FOR THE SYNTHESIS OF COMPOUNDS 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) PHENYL) - ETOXI) - METAL] - 8 PHENYL - 1,7- DIAZA - ESPIRO (4, 5) DECAN - 2 ONA
AR065802A1 (en) 2007-03-22 2009-07-01 Schering Corp FORMULATIONS OF TABLETS CONTAINING SALTS OF 8- [(1- (3,5- BIS- (TRIFLUOROMETIL) FENIL) -ETOXI) - METHYL) -8- PHENYL -1, 7- DIAZA- SPIRO [4,5] DECAN - 2- ONA AND TABLETS PREPARED FROM THESE
CN102203062B (en) 2008-09-05 2014-12-17 欧科生医股份有限公司 Process and intermediates for the synthesis of 8-[{1-(3,5-bis-(trifluoromethyl)phenyl)-ethoxy}-methyl]-8-phenyl-1,7-diaza-spiro[4.5]decan-2-one compounds
RU2017145628A (en) 2009-08-14 2019-02-19 ОПКО Хельс, Инк. COMPOSITIONS OF NEUROKININ-1 ANTAGONISTS FOR INTRAVENOUS INTRODUCTION

Also Published As

Publication number Publication date
EP2464230A1 (en) 2012-06-20
IL217942A0 (en) 2012-03-29
EP2464230B1 (en) 2016-10-05
AU2010282483B2 (en) 2014-09-04
US9101615B2 (en) 2015-08-11
CN105503870A (en) 2016-04-20
KR20120060215A (en) 2012-06-11
ES2609640T3 (en) 2017-04-21
JP2016041734A (en) 2016-03-31
WO2011019911A1 (en) 2011-02-17
KR101834577B1 (en) 2018-03-05
EP3143996A1 (en) 2017-03-22
JP2013501806A (en) 2013-01-17
RU2017145628A (en) 2019-02-19
MX336071B (en) 2016-01-06
RU2012109405A (en) 2013-09-20
SG178403A1 (en) 2012-03-29
TW201111382A (en) 2011-04-01
JP5860399B2 (en) 2016-02-16
US20110038925A1 (en) 2011-02-17
AU2010282483A1 (en) 2012-03-01
BR112012003263A2 (en) 2015-09-22
RU2642234C2 (en) 2018-01-24
CA2770403C (en) 2020-09-01
CA2770403A1 (en) 2011-02-17
MX2012001872A (en) 2012-04-11
TWI498329B (en) 2015-09-01
CN102573475B (en) 2016-01-20
TW201604195A (en) 2016-02-01
US20160024092A1 (en) 2016-01-28
EP2464230A4 (en) 2013-01-02
CN102573475A (en) 2012-07-11
JP6308991B2 (en) 2018-04-11

Similar Documents

Publication Publication Date Title
SG10201407538WA (en) Intravenous formulations of neurokinin-1 antagonists
MX2021008356A (en) Jak2 and alk2 inhibitors and methods for their use.
MX2018011831A (en) SOLUBLE C5aR ANTAGONISTS.
MX2020010151A (en) 1,4-disubstituted pyridazine analogs and methods for treating smn-deficiency-related conditions.
MX2013003019A (en) Azabenzothiazole compounds, compositions and methods of use.
MX2016001400A (en) 1,4-disubstituted pyridazine derivatives and their use for treating smn-deficiency-related conditions.
IN2012DN03337A (en)
MX2011013771A (en) 1, 3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17.
UA109868C2 (en) N -alkyltriazole compounds asr
HK1149258A1 (en) Compounds
UA105229C2 (en) Pharmaceutical formulation
GEP20186880B (en) 2-amino-3, 5, 5-trifluoro-3, 4, 5, 6-tetrahydropyridines as bace1 inhibitors for treatment of alzheimer's disease
MX2009009238A (en) Novel phosphodi esterase inhibitors.
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MX2013000474A (en) Novel arylamide derivatives having antiandrogenic properties.
MX2010002584A (en) Piperidine derivatives as agonists of muscarinic receptors.
IN2012DN01232A (en)
IN2012DN04868A (en)
WO2014062838A3 (en) Pkm2 modulators and methods for their use
MX2010009756A (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof.
MX2010009395A (en) Muscarinic receptor agonists, compositions, methods of treatment thereof, and processes for preparation thereof 177.
TN2014000060A1 (en) Benzothiazolone compound
WO2015002755A3 (en) Compounds for the treatment of malaria
MY156955A (en) Antifungal agents
IN2012DN01234A (en)